Gemfibrozil

BRAND NAMES

The most recognized brand name for gemfibrozil is Lopid, originally manufactured by Pfizer. It is used to lower high cholesterol and triglyceride levels, and is also commonly available in generic form simply as gemfibrozil.

MECHANISM OF ACTION

Gemfibrozil is a fibrate-class lipid-lowering drug that primarily works by activating peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor that regulates genes involved in lipid metabolism. Activation of PPAR-α increases the synthesis and activity of lipoprotein lipase, which enhances the breakdown and clearance of triglyceride-rich lipoproteins such as very-low-density lipoproteins (VLDL) and chylomicrons from the bloodstream. At the same time, it reduces hepatic production of VLDL by decreasing the availability of triglycerides in the liver. This dual action leads to a significant reduction in serum triglyceride levels and a moderate increase in high-density lipoprotein (HDL) cholesterol. Additionally, it promotes fatty acid oxidation in the liver, further contributing to improved lipid profile and reduced risk of pancreatitis in patients with severe hypertriglyceridemia.

PHARMACOKINETICS

Absorption: Well absorbed after oral administration, but food reduces absorption; therefore, it is recommended to take it about 30 minutes before morning and evening meals.

Distribution: Highly bound to plasma albumin.(97-99%)

Metabolism: Extensively metabolized in the liver into metabolites such as hydroxymethyl, carboxyl, and other related derivatives.

Elimination: Primarily excreted in urine (about 70%), with the remaining portion eliminated in feces.

PHARMACODYNAMICS

Gemfibrozil is a fibrate-class lipid-lowering agent whose pharmacodynamic effects are mainly mediated through activation of peroxisome proliferator-activated receptor alpha (PPAR-α). This activation increases transcription of genes involved in lipid metabolism, leading to enhanced lipoprotein lipase activity and increased clearance of triglyceride-rich lipoproteins such as VLDL and chylomicrons. It also reduces hepatic synthesis of triglycerides and apolipoprotein C-III (an inhibitor of lipoprotein lipase), resulting in a marked decrease in serum triglycerides. Additionally, it modestly increases HDL cholesterol by promoting apolipoprotein A-I and A-II production, thereby improving overall lipid profile and reducing atherogenic risk.

DOSAGE AND STRENGTH

Formulation: Gemfibrozil is available as 600 mg tablets and 300 mg capsules.

Administration: It is usually taken in divided doses, preferably before meals.

Dose adjustment: The dosage is individualized based on patient response and lipid levels, as directed by a healthcare provider.

Missed dose: If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose.

FOOD INTERACTIONS

Gemfibrozil has important food-related considerations: it is best taken 30 minutes before meals because food can reduce its absorption and overall effectiveness. High-fat or heavy meals may further decrease drug absorption, so consistent timing relative to meals is important for optimal lipid-lowering effect. Alcohol intake should be limited or avoided, as it can worsen triglyceride levels and increase the risk of liver-related side effects.

DRUG INTERACTIONS

Gemfibrozil has several important drug interactions, mainly due to effects on drug metabolism and increased risk of toxicity. It significantly increases the risk of myopathy and rhabdomyolysis when used with statins (especially simvastatin and lovastatin), so this combination is generally avoided. It can enhance the effects of oral anticoagulants like warfarin by displacing them from protein binding sites, increasing bleeding risk and requiring close INR monitoring. It may also interact with antidiabetic drugs (e.g., sulfonylureas), increasing the risk of hypoglycemia. In addition, it can alter the metabolism of other drugs through inhibition of hepatic enzymes and glucuronidation pathways, potentially increasing their plasma concentrations and toxicity.

CONTRAINDICATIONS

Gemfibrozil is contraindicated in patients with severe liver or kidney impairment, existing gallbladder disease, or known hypersensitivity to the drug. It should also not be used with certain medications such as simvastatin, repaglinide, or dasabuvir due to a significantly increased risk of serious adverse effects, including severe myopathy, rhabdomyolysis, or elevated drug concentrations.

SIDE EFFECTS

Common side effects:

• Abdominal pain and dyspepsia

• Nausea and vomiting

• Diarrhea

• Headache

• Dizziness

• Rash or mild skin reactions

• Fatigue

• Muscle pain (myalgia)

• Muscle weakness

• Rare risk of myopathy

• Elevated liver enzymes

• Rare hepatotoxicity

Serious but rare effects:

• Rhabdomyolysis

• Gallstones (cholelithiasis)

• Severe allergic reactions

• Blood disorders (e.g., anemia, leukopenia)

OVERDOSE

Gemfibrozil overdose is a medical emergency and requires immediate contact with emergency services or a poison control center. It may present with severe gastrointestinal symptoms such as abdominal pain, nausea, vomiting, and diarrhea, along with marked muscle or joint pain and, in severe cases, acute kidney injury. Management is supportive, as there is no specific antidote, and focuses on symptomatic treatment and monitoring of organ function.

TOXICITY

Gemfibrozil toxicity mainly presents as gastrointestinal symptoms such as dyspepsia, along with muscle-related effects like myopathy and liver toxicity. A rare but serious complication is rhabdomyolysis, especially when used with statins. Other important toxic effects include elevated liver enzymes, gallstone formation (cholelithiasis), and, in rare cases, kidney failure or acute abdominal conditions such as appendicitis.